Pappas Capital
Pappas Capital is a global venture capital and commercial development firm that invests in life science, agriculture, and technology companies. The firm operates three lines of business—Pappas Ventures (life science venture arm), Specialized Fund Management (custom investment vehicles), and Translational Medicine (academic partnerships)—and provides capital and commercial development support to advance research from concept toward commercialization. The site states the firm has invested for 31 years and in more than 100 companies across the United States, Canada and Asia.
Industries
Nr. of Employees
small (1-50)
Pappas Capital
Durham, North Carolina, United States, North America
Portfolio
Announced initiation of a Phase 1B clinical trial for a nectin-4 targeting radiopharmaceutical product candidate (news dated May 28, 2025).
#Oncology / radiopharmaceuticals
Site includes multiple portfolio news items: $90M Series B (Sept 5, 2018), $75M Series C (June 16, 2020), and IPO pricing (Dec 10, 2020; 8.4M shares at $23.00/share, expected gross proceeds ~$193.2M). Also announced first patient dosed in Phase 1/2 trial for 4D-125 (Aug 19, 2020).
#Gene therapy / AAV vector development
Presented in vitro and in vivo data showing near-complete repression of HBV RNA using Tune-401 (news dated Nov 19, 2024).
#Epigenome editing / RNA therapeutics
Article notes a $18M financing round and describes development of a small-molecule approach intended to improve cognitive function in intellectual disability conditions (MedCity News, March 19, 2015).
#Neurology / intellectual disability therapeutics
Site includes multiple items: private placement of $50.1M (Aug 18, 2010) and Phase 2a positive RVR results with ACH-1625 for HCV (Mar 30, 2011).
#Infectious disease / antivirals
News item notes appointment of Howard Doran as President and CEO (Jan 22, 2014).
#Diagnostics / IVD
Announced initiation of a Phase 1B clinical trial for a nectin-4 targeting radiopharmaceutical product candidate (news dated May 28, 2025).
#Oncology / radiopharmaceuticals
Site includes multiple portfolio news items: $90M Series B (Sept 5, 2018), $75M Series C (June 16, 2020), and IPO pricing (Dec 10, 2020; 8.4M shares at $23.00/share, expected gross proceeds ~$193.2M). Also announced first patient dosed in Phase 1/2 trial for 4D-125 (Aug 19, 2020).
#Gene therapy / AAV vector development
Presented in vitro and in vivo data showing near-complete repression of HBV RNA using Tune-401 (news dated Nov 19, 2024).
#Epigenome editing / RNA therapeutics
Article notes a $18M financing round and describes development of a small-molecule approach intended to improve cognitive function in intellectual disability conditions (MedCity News, March 19, 2015).
#Neurology / intellectual disability therapeutics
Site includes multiple items: private placement of $50.1M (Aug 18, 2010) and Phase 2a positive RVR results with ACH-1625 for HCV (Mar 30, 2011).
#Infectious disease / antivirals
News item notes appointment of Howard Doran as President and CEO (Jan 22, 2014).
#Diagnostics / IVD